Pact for Eylea SR with Regeneron Pharma brings Ocular upside at back end
By Randy Osborne
Thursday, October 13, 2016
Ocular Therapeutix Inc.'s potential $315 million pact with Regeneron Pharmaceuticals Inc. brought no up-front payment and only $10 million upon the exercise of an option – a carefully considered move, said Chief Financial Officer Brad Smith.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.